Glomerular fibrin thrombi in ABO and crossmatch compatible renal allograft biopsies

Pathology Research and Practice

Volumn 207, Issue 1, 2011, Pages 15-23

  Troxell, Megan L ^a   Norman, Douglas ^b   Mittalhenkle, Anuja ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acute allograft rejection; C4d; Calcineurin inhibitor toxicity; Fibrin thrombi; Thrombotic microangiopathy

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN; DACLIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; BIOPSY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; CAPILLARITIS; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULITIS; GLOMERULUS FIBRIN THROMBUS; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ALLOGRAFT BIOPSY; KIDNEY ALLOGRAFT REJECTION; KIDNEY INFARCTION; OUTCOME ASSESSMENT; PLASMAPHERESIS; RETROSPECTIVE STUDY; STAINING; THROMBUS;

ABO BLOOD-GROUP SYSTEM; BIOPSY; BLOOD GROUPING AND CROSSMATCHING; COMPLEMENT C4B; FIBRIN; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; THROMBOSIS; THROMBOTIC MICROANGIOPATHIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78650245447     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.10.001     Document Type: Article

References (50)

1. Amico P., Honger G., Bielmann D., et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008, 85:1557-1563.
2. Bennett W.M., Hansen K.S., Houghton D.C., et al. Disseminated intravascular coagulation (DIC) in a kidney donor associated with transient recipient DIC. Am. J. Transplant. 2005, 5:412-414.
3. Collins A.B., Schneeberger E.E., Pascual M.A., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 1999, 10:2208-2214.
4. Colvin R., Nickeleit V. Renal transplant pathology. Heptinstall's Pathology of the Kidney 2007, 1349-1460. Lippincott, Williams & Wilkins, Philadelphia, PA. J.C. Jennette (Ed.).
5. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 2007, 18:1046-1056.
6. Cosio F.G., Lager D.J., Lorenz E.C., et al. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010, 89:1088-1094.
7. Dragun D., Muller D.N., Brasen J.H., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005, 352:558-569.
8. Fass L., Herberman R.B. A cytotoxic antiglobulin technique for assay of antibodies to histocompatibility antigens. J. Immunol. 1969, 102:140-144.
9. Fidler M.E., Gloor J.M., Lager D.J., et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am. J. Transplant. 2004, 4:101-107.
10. Fuggle S.V., Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008, 86:384-390.
11. Gibson I.W., Gwinner W., Brocker V., et al. Peritubular capillaritis in renal allografts: prevalence, scoring system, reproducibility and clinicopathological correlates. Am. J. Transplant. 2008, 8:819-825.
12. Golconda M.S., de Mattos A.M., Prather J., et al. Renal transplantation at Oregon Health and Science University: recent results and protocols. Clin. Transpl. 2003, 149-154.
13. Haas M., Bohmig G.A., Leko-Mohr Z., et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol. Dial. Transplant. 2002, 17:1503-1508.
14. Haas M., Rahman M.H., Racusen L.C., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am. J. Transplant. 2006, 6:1829-1840.
15. Hochstetler L.A., Flanigan M.J., Lager D.J. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am. J. Kidney Dis. 1994, 23:444-450.
16. Hourmant M., Buzelin F., Dantal J., et al. Late acute failure of well-HLA-matched renal allografts with capillary congestion and arteriolar thrombi. Transplantation 1995, 60:1252-1260.
17. Iwaki Y., Cook D.J., Terasaki P.I., et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant. Proc. 1987, 19:764-766.
18. Karthikeyan V., Parasuraman R., Shah V., et al. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am. J. Transplant. 2003, 3:1289-1294.
19. Lasik Z.G., Silva F.G. Hemolytic-uremia syndrome, thrombotic thrombocytopenic pupura, and other thrombotic microangiopathies. Heptinstall's Pathology of the Kidney 2007, 702-752. Lippincott, Williams & Wilkins, Philadelphia, PA. J.C. Jennette (Ed.).
20. Mauiyyedi S., Crespo M., Collins A.B., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol. 2002, 13:779-787.
21. Mengel M., Bogers J., Bosmans J.L., et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am. J. Transplant. 2005, 5:1050-1056.
22. Miller B.W., Hmiel S.P., Schnitzler M.A., et al. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am. J. Kidney Dis. 1997, 29:813-814.
23. Mizutani K., Terasaki P., Hamdani E., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am. J. Transplant. 2007, 7:1027-1031.
24. Mor E., Lustig S., Tovar A., et al. Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection?. Transplant. Proc. 2000, 32:686-687.
25. Murer L., Zacchello G., Bianchi D., et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J. Am. Soc. Nephrol. 2000, 11:1132-1137.
26. Neild G.H., Taube D.H., Hartley R.B., et al. Morphological differentiation between rejection and cyclosporin nephrotoxicity in renal allografts. J. Clin. Pathol. 1986, 39:152-159.
27. Nickeleit V. The pathology of kidney transplantation. Transplantation Pathology 2009, 45-111. Cambridge University Press, New York. P. Ruiz (Ed.).
28. Nickeleit V., Zeiler M., Gudat F., et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J. Am. Soc. Nephrol. 2002, 13:242-251.
29. Nishi H., Hanafusa N., Kondo Y., et al. Clinical outcome of thrombotic microangiopathy after living-donor liver transplantation treated with plasma exchange therapy. Clin. J. Am. Soc. Nephrol. 2006, 1:811-819.
30. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 1969, 280:735-739.
31. Pei R., Wang G., Tarsitani C., et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum. Immunol. 1998, 59:313-322.
32. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 2003, 3:708-714.
33. Racusen L.C., Halloran P.F., Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am. J. Transplant. 2004, 4:1562-1566.
34. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999, 55:713-723.
35. Randhawa P.S., Tsamandas A.C., Magnone M., et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am. J. Surg. Pathol. 1996, 20:306-312.
36. Schwimmer J., Nadasdy T.A., Spitalnik P.F., et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am. J. Kidney Dis. 2003, 41:471-479.
37. Scornik J.C., Guerra G., Schold J.D., et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am. J. Transplant. 2007, 7:1808-1814.
38. Setoguchi K., Ishida H., Shimmura H., et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am. J. Transplant. 2008, 8:86-94.
39. Sis B., Jhangri G.S., Bunnag S., et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am. J. Transplant. 2009, 9:2312-2323.
40. Solez K., Colvin R.B., Racusen L.C., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am. J. Transplant. 2008, 8:753-760.
41. Sun Q., Liu Z., Chen J., et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin. J. Am. Soc. Nephrol. 2008, 3:1479-1486.
42. Trimarchi H.M., Truong L.D., Brennan S., et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999, 67:539-544.
43. Troxell M.L., Weintraub L.A., Higgins J.P., et al. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin. J. Am. Soc. Nephrol. 2006, 1:583-591.
44. Trpkov K., Campbell P., Pazderka F., et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading system. Transplantation 1996, 61:1586-1592.
45. Vasilescu E.R., Ho E.K., Colovai A.I., et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum. Immunol. 2006, 67:597-604.
46. Waiser J., Budde K., Rudolph B., et al. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am. J. Kidney Dis. 1999, 34:556-559.
47. Young B.A., Marsh C.L., Alpers C.E., et al. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am. J. Kidney Dis. 1996, 28:561-571.
48. Zarifian A., Meleg-Smith S., O'Donovan R., et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999, 55:2457-2466.
49. Zent R., Katz A., Quaggin S., et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin. Nephrol. 1997, 47:181-186.
50. Zou Y., Stastny P., Susal C., et al. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 2007, 357:1293-1300.